ResApp Health Ltd's (ASX:RAP) executive director, Brian Leedman, has provided support for the company's valuation through the purchase of 876,000 shares on-market this week for a consideration of $64,500.
Leedman's stake in the company is now 21.5 million shares, along with 18.75 million performance shares and several lines of director incentive options.
A separate company holding has 4.5 million shares, along with the same number of performance shares.
ResApp has a business strategy of developing smartphone applications for the diagnosis and management of respiratory disease.
Shares in the company have climbed 9.3% today to $0.082. A year earlier shares were trading in the mid $0.40 range.